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Abstract Several neuropeptide FF (NPFF)-related peptides,
known as modulators of the opioid system, have been previously
characterized in bovine and rodent brain. Reverse-phase high
pressure liquid chromatography (HPLC) fractions of a human
with normal pressure hydrocephalus cerebrospinal £uid (CSF),
co-migrating with NPFF-related synthetic peptides, were char-
acterized by capillary HPLC coupled on-line to nanospray ion
trap tandem mass spectrometry. Two peptides present in the
pro-NPFFA precursor, NPAF (AGEGLNSQFWSLAAPQRF-
NH2) and NPSF (SLAAPQRF-NH2), were identi¢ed. The
monitoring of NPFF-related peptides in human CSF can be
helpful to understand their roles in pain sensitivity.
/ 2002 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
The knowledge of the mammalian endogenous anti-opioid
neuropeptide FF (NPFF, FLFQPQRF-NH2) system has re-
cently been greatly improved by the identi¢cation of two re-
ceptors, NPFF1 [1,2] and NPFF2 [1^3], and by the character-
ization of two precursor proteins (pro-NPFFA and pro-
NPFFB [2]) predicted to generate peptides carrying a homol-
ogous sequence in their C-terminal part [1,2,4,5]. Among
those peptides, NPFF and neuropeptide AF (NPAF,
AGEGLSSPFWSLAAPQRF-NH2) have been identi¢ed in
bovine brain and have been shown to modulate the analgesic
e¡ects of morphine in rodents [6]. Both peptides possess the
C-terminal sequence PQRF-NH2, essential for their interac-
tions with NPFF receptors [7]. More recently, on the basis of
the di¡erence in the sequences of precursors between species
[4,5], several NPFF-related peptides containing either the
NPFF or the NPAF C-terminal sequence (NPSF,
SLAAPQRF-NH2) have been isolated in rodents [8,9]. More-
over, a second precursor belonging to this family has been
described also exhibiting a PQRF-NH2 C-terminus [2] and a
corresponding octadecapeptide has recently been identi¢ed in
rat brain [10]. The a⁄nity of this peptide to NPFF receptors,
however, remains to be determined.
The human genes encoding pro-NPFFA and pro-NPFFB
have been cloned [1,2,4,5]. According to their amino acid se-
quence and to the presence of putative cleavage motifs, two
peptides ending in PQRF-NH2 may be predicted to be ma-
tured from human pro-NPFFA and one from human pro-
NPFFB in NPFF neurons and should be released in the extra-
cellular space. The ¢rst one from pro-NPFFA corresponds to
the NPFF sequence extended by SQA in the N-terminus
(SQA-NPFF, SQAFLFQPQRF-NH2) (Fig. 1). The second
one is an octadecapeptide (hNPAF, AGEGLNSQFW-
SLAAPQRF-NH2), which di¡ers by two amino acids from
the bovine NPAF. An octapeptide (NPVF, VPNLPQRF-
NH2) is expected from pro-NPFFB (Fig. 1) [1].
In the present study we have investigated the presence in
human cerebrospinal £uid (CSF) of NPFF-related peptides
ending in PQRF-NH2 and predicted to be generated from
pro-NPFFA and pro-NPFFB. CSF was obtained during the
changing of a ventriculo-peritoneal shunting valve in a patient
with normal pressure hydrocephalus to improve clinical symp-
toms by evacuating CSF. Therefore, a large volume of CSF
could be obtained which could contain several NPFF-related
peptides originating from di¡erent regions of the brain. In
fact, whereas the tissue localization of both precursors is
largely unknown in human brain, pro-NPFFB as well as
pro-NPFFA mRNA have been detected in rat, particularly
in hypothalamus [4,11].
High performance liquid chromatography (HPLC) fractions
of CSF, co-migrating with peptide standards, were subjected
to further characterization by capillary HPLC coupled on-line
to nanospray ion trap tandem mass spectrometry (nanospray
MS/MS) which has proven to be an e⁄cient tool for the
characterization of neuropeptides in biological samples
[10,12].
2. Materials and methods
2.1. Chemicals
NPFF-related peptides were synthesized by the solid-phase method
using FMOC chemistry as previously described [13]. FMOC amino
acid derivatives were purchased from Bachem, France. Iodination of
[D-Tyr1,(NMe)Phe3]NPFF was performed according to Dupouy and
Zajac [14].
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2.2. CSF sample
CSF was collected from a 74 year old patient with normal pressure
hydrocephalus during the changing of a shunting ventriculo-peritoneal
valve for a valve dysfunction with the informed consent of the patient.
CSF was collected from an external catheter at 08.00 h and immedi-
ately frozen at 320‡C. After centrifugation of a 20 ml CSF sample
(2000Ug for 10 min at 4‡C), supernatant was lyophilized and stored
at 380‡C until HPLC analysis. Protein concentration in CSF before
lyophilization was 0.84 mg/ml.
2.3. HPLC procedures
The HPLC system consisted of a solvent delivery pump (ICS,
France) and an injection valve model rheodyne with a 500 Wl loop.
Dried CSF was dissolved in mobile phase in order to get a protein
concentration of 2 mg/ml.
Diluted CSF samples (500 Wl per run, 12 runs) were applied to a C8
Aquapore RP300 Brownlee (4.6U200 mm) (HPLC-1). The column
was equilibrated with 70% mobile phase A (0.09% tri£uoroacetic
acid in water) and 30% mobile phase B (0.09% tri£uoroacetic acid
in 75% acetonitrile) at a £ow rate of 400 Wl/min. Elution was achieved
by 30% B for 6 min, followed by a linear gradient of 30^60% B during
50 min. HPLC fractions of 1 min (0.4 ml), starting at the injection
time, from 12 separate runs were pooled and lyophilized.
Fractions co-migrating with NPSF and NPVF were subjected to a
second HPLC separation (HPLC-2). The column C8 Aquapore RP300
Brownlee (4.6U200 mm) was equilibrated with 94% mobile phase A
(0.09% tri£uoroacetic acid in water) and 6% mobile phase B (0.09%
tri£uoroacetic acid in 75% acetonitrile) at a £ow rate of 400 Wl/min.
Elution was achieved by a linear gradient of 6^60% B during 56 min.
Fractions of 0.4 ml were collected.
Fractions co-migrating with SQA-NPFF, NPFF and hNPAF were
subjected to a second HPLC separation on a Spheri-5 RP-8S 5 Wm
Brownlee (2.1U220 mm) (HPLC-3). The column was equilibrated
with 98% mobile phase A (0.09% tri£uoroacetic acid in water) and
2% mobile phase B (0.09% tri£uoroacetic acid in 75% acetonitrile) at a
£ow rate of 400 Wl/min. Elution was achieved by 2% B for 6 min,
followed by a linear gradient of 2^80% B during 50 min. Fractions of
0.4 ml were collected.
2.4. Radioimmunoassay (RIA)
RIA was performed on samples analyzed by mass spectrometry
using a NPFF antiserum. The NPFF-related peptide concentration
in samples was determined according to calibration curves of the
corresponding synthetic peptide. The method of obtaining NPFF anti-
serum and the RIA procedure have been previously described [9].
2.5. On-line capillary HPLC/nanospray MS/MS
HPLC fractions collected using either the HPLC-2 or the HPLC-3
procedure were concentrated under vacuum and analyzed by on-line
capillary HPLC/nanospray MS/MS. The sample was injected onto a
C18 PepMap1 (LC Packings) column (75 WmU150 mm). The sepa-
ration was achieved using an isocratic elution at 0% B for 2 min
followed by a linear gradient of 0^40% B in 38 min at a £ow rate
of 150 nl/min. Solvent A was 0.1% formic acid in H2O/CH3CN (99/1
v/v) and solvent B was 0.1% formic acid in H2O/CH3CN (10/90 v/v).
The eluent was introduced into an LCQ Deca ion trap mass spec-
trometer (ThermoFinnigan, San Jose, CA, USA) through a nano£ow
needle (New Objective, Cambridge, MA, USA) at 2.0 kV. MS/MS
data were acquired using a three m/z unit ion isolation window and
a relative collision energy of 35%.
3. Results
3.1. HPLC separation of NPFF-related peptides
In order to identify NPFF-related peptides in CSF, the
corresponding synthetic peptides were ¢rst separated by suc-
cessive HPLC and their fractions of elution were determined
(Fig. 1 and Table 1). Inter-day coe⁄cient of variation in re-
tention time was less than 5% for all peptides in all HPLC
conditions except for NPSF and NPVF in HPLC-1 conditions
(less than 10%). CSF was subjected to the same HPLC runs
and fractions of interest corresponding to the fractions of
elution of synthetic peptides (Table 1) were collected. Adja-
cent fractions were combined to take into account inter-day
variations in peptide migration and were lyophilized before
MS analysis.
3.2. Identi¢cation of hNPAF and NPSF by mass spectrometry
Synthetic hNPAF (doubly charged ion at m/z 990.0) and
NPSF (singly charged ion at m/z 888.5) were ¢rst analyzed by
on-line capillary HPLC/nanospray MS/MS and showed reten-
tion times of 42.2 min and 28.6 min in the capillary HPLC
system, respectively (Fig. 2A,C). Analyses of the HPLC frac-
tions collected from the CSF sample, the retention time of
which corresponded to that of hNPAF and NPSF, were
then performed, taking care to avoid any carry over from
one injection to the other. In each case, a peak of the appro-
priate m/z value at the retention time of the corresponding
synthetic peptide was detected (Fig. 2B,D). The unambiguous
identi¢cation of each neuropeptide was then given by the MS/
MS data.
The MS/MS spectrum of the synthetic hNPAF peptide dis-
played a series of y and b fragment ions, including an intense
y4 fragment ion at m/z 546.3 (Fig. 3A). This fragment corre-
sponds to the C-terminal PQRF-NH2 sequence, which is a
characteristic feature of all expected NPFF-related peptides.
MS/MS analysis of the peak detected in the HPLC fraction
corresponding to hNPAF of the CSF sample is displayed in
Fig. 3B. The MS/MS fragmentation pattern observed is iden-
tical to the fragmentation pattern of synthetic hNPAF and
thus unambiguously identi¢es hNPAF in the CSF sample.
Similarly, the MS/MS spectrum of the synthetic NPSF pep-
tide displayed a series of y fragment ions, including the char-
acteristic y4 fragment ion corresponding to the PQRF-NH2
C-terminal sequence (Fig. 4A). The MS/MS fragmentation pat-
tern of the peak detected in the HPLC fraction corresponding
to NPSF of the CSF sample is identical to the fragmentation
pattern of the corresponding synthetic peptide (Fig. 4B).
NPSF is thus unambiguously identi¢ed in the CSF sample.
The three other NPFF-related peptides (NPVF, SQA-
Table 1
Reliability of the procedure: HPLC fractions of elution, RIA speci¢city and MS/MS detection limits of NPFF-related synthetic peptides
HPLC-1 fraction
number
HPLC-2 fraction
number
HPLC-3 fraction
number
RIA IC50 (fmol) MS/MS detection
limit (fmol)
SQA-NPFF 35R 1 ^ 43R 1 33 10
NPFF 35R 1 ^ 44R 1 30 10
hNPAF 41R 1 ^ 45R 1 420 20
NPSF 13R 1 35R 1 ^ 867 1
NPVF 14R 1 38R 1 ^ 1500 1
HPLC fractions corresponded to 1 min elution.
The MS/MS detection limit was de¢ned as the minimum amount of peptide necessary to unambiguously identify its speci¢c MS/MS fragmenta-
tion pattern.
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NPFF, and NPFF), which could also be expected, were not
detected in the CSF sample using this approach.
The HPLC fractions of CSF analyzed by mass spectrometry
were also subjected to a RIA using an antiserum anti-NPFF.
The mean IC50 values obtained from independent experiments
(nv 3) with synthetic peptides are presented in Table 1. Inter-
assay coe⁄cient of variation was less than 15%. hNPAF and
NPSF immunoreactivities were estimated to be 35 and 100
fmol/ml CSF, respectively. NPVF immunoreactivity was esti-
mated at 100 fmol/ml CSF, SQA-NPFF at 7 fmol/ml and
NPFF 12 fmol/ml. The amounts of hNPAF and NPSF de-
tected during the mass spectrometric analyses were estimated
to be around 50 fmol and 5 fmol, respectively, according to
the signal intensity observed for 100 fmol of synthetic hNPAF
and 60 fmol of synthetic NPSF (Fig. 2). The amounts of
hNPAF and NPSF in the CSF were then estimated to be
around 20 and 10 fmol/ml, respectively.
4. Discussion
We report here on the availability of a reliable method to
identify and quantify NPFF peptides, which led for the ¢rst
Fig. 1. NPFF-related peptides in human pro-NPFFA and pro-NPFFB sequences. G : amidation site.
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Fig. 2. Capillary HPLC/nanospray MS analyses of hNPAF and NPSF. Reconstructed ion chromatograms of (A) 100 fmol of synthetic hNPAF
(doubly charged ion at m/z 990.0), (B) collected HPLC fraction (40^42 min HPLC-1 and 41^44 min HPLC-3) of CSF sample at m/z 990.0
(doubly charged ion of hNPAF), (C) 60 fmol of synthetic NPSF (singly charged ion at m/z 888.5), (D) collected HPLC fraction (12^14 min
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time to the characterization in human CSF of two peptides,
NPSF and hNPAF, derived from pro-NPFFA. The strategy is
based on the analysis of untreated CSF by successive HPLC
separations followed by on-line capillary HPLC/nanospray
MS/MS analyses. This MS/MS procedure allows the unambig-
uous identi¢cation of femtomoles of neuropeptides by their
speci¢c fragmentation pattern.
This study was performed on CSF collected from a shunt-
ing valve of a patient with normal pressure hydrocephalus in
order to obtain a large volume of sample of ventricular origin
which could contain peptides issued from both NPFF precur-
sors. Mass spectrometry did not evidence NPVF, SQA-NPFF
or NPFF whereas RIA analysis revealed NPFF-like immuno-
reactivity.
NPFF-like immunoreactivity has been previously evidenced
in human plasma and CSF [15^17] suggesting that NPFF-
related peptides of neuronal origin circulate in human biolog-
ical £uids. A major peak of immunoreactivity, coeluting with
synthetic NPFF, was observed using HPLC separation
[15,16]. It could not be excluded that immunoreactivity co-
eluting with NPFF could represent another NPFF-related
peptide such as SQA-NPFF. This hypothesis is supported,
in our study, by the coelution of SQA-NPFF and NPFF in
the conditions of the ¢rst HPLC. After a second HPLC 7
fmol/ml SQA-NPFF immunoreactivity and 12 fmol/ml
NPFF immunoreactivity were quanti¢ed in human CSF.
The previous study of Sundblom et al. [16] reported 1.5
fmol/ml NPFF immunoreactivity. This discrepancy may be
explained by the origin of the CSF. In the study of Sundblom
et al. [16], the CSF was collected by lumbar punction of
healthy volunteers or chronic pain patients, whereas in the
present study, CSF was of ventricular origin from a patient
with normal pressure hydrocephalus. Gradients between ven-
tricular and lumbar CSF of several neurotransmitters and
neuropeptides have been reported [18]. Furthermore, changes
in CSF concentration of several neuropeptides have been ob-
served in patients with normal pressure hydrocephalus [18].
The presence of SQA-NPFF and NPFF was not con¢rmed
by mass spectrometry analysis but the amount of these pep-
tides estimated by RIA is close to their limit of detection in
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mass spectrometry. Another possibility is that the immunore-
activity observed is not due to SQA-NPFF and NPFF but to
unknown peptides eluting at the same retention times in our
HPLC conditions and cross-reacting with the NPFF antise-
rum. This latter hypothesis is likely to apply to NPVF, an
octapeptide predicted to be matured from pro-NPFFB in hu-
mans. Its amount was estimated to be 100 fmol/ml CSF by
RIA, and it was not detected by mass spectrometry. In this
case, the estimated amount of NPVF was high enough to
allow its characterization by mass spectrometry.
In this study, we identi¢ed hNPAF and NPSF by mass
spectrometry in human CSF. NPSF represents the C-terminal
part of hNPAF but is not preceded in pro-NPFFA by a cleav-
age motif suggesting that it is a fragment issued from a longer
peptide by enzymatic degradation inside the neurons, in the
extracellular liquid of nervous tissue and/or in the CSF. This
peptide has also been isolated from nervous tissue of mouse
and rat [8,9]. In contrast to hNPAF, NPSF displays a weak
a⁄nity for NPFF1 and NPFF2 receptors [19]. However, when
intracerebroventricularly injected, these two peptides reverse
morphine-induced analgesia in rodents [6,9]. In contrast, in-
trathecal injection of NPSF enhances morphine-induced anal-
gesia in rat [20]. These results suggest a physiological role of
these peptides in the nervous system by modulation of the
opioid system.
Receptors for NPFF have been localized in human spinal
sensory system by autoradiography [21] and NPFF2 RNA
expression has been detected in many brain regions [2]. In
the present study, the identi¢cation in human CSF of
NPFF-related peptides strongly suggests that pro-NPFFA
protein expressed in human nervous system is also matured
to generate some peptides resistant to peptidase degradation
able to di¡use in the CSF biological £uid and to act at dis-
tance of their site of synthesis.
The monitoring of NPFF-related peptides in human CSF
can be helpful to understand their roles in pain sensitivity.
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